Aspirin and Extended-Release Dipyridamole Capsules, 25mg/200 mg, 60-count bottle, Rx Only, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, Product of India, NDC 68462-405-60.
Published July 27, 2022 · Recall initiated: June 29, 2022
Summary
FDA records drug Class III recall D-1282-2022, published July 27, 2022 and initiated June 29, 2022. Recalling firm: Glenmark Pharmaceuticals Inc., USA; Status: Ongoing; Reported quantity: 168936 bottles; Lot: Lot#: 17201639, Exp 08/2022; 17201759, Exp 09/2022; 17202067, Exp 10/2022; 17210696, Exp 02/2023; 17210092, Exp 11/2022; 17210145, Exp 12/2022; 17210732, Exp 02/2023; 17211062, Exp 04/2023; 17211441, Exp 05/2023; 17211670, Exp 06/2023; 17211810, Exp 07/2023; 17211862, 17212020, 17212068, Exp 08/2023; 17212438, Exp 10/2023; 17220172, 17220251, Exp 12/2023. Class III means the product is not likely to cause adverse health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Failed Tablet/Capsule Specification : Capsule breakage
What to do
Voluntary: Firm initiated · Letter
Get an email if ASPRIN AND EXTENDED-RELEASE DIPYRIDAMOLE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- ASPRIN AND EXTENDED-RELEASE DIPYRIDAMOLE
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Distributor
- USA Nationwide
- UPC
- 0368462405604
- Lot
- Lot#: 17201639, Exp 08/2022; 17201759, Exp 09/2022; 17202067, Exp 10/2022; 17210696, Exp 02/2023; 17210092, Exp 11/2022; 17210145, Exp 12/2022; 17210732, Exp 02/2023; 17211062, Exp 04/2023; 17211441, Exp 05/2023; 17211670, Exp 06/2023; 17211810, Exp 07/2023; 17211862, 17212020, 17212068, Exp 08/2023; 17212438, Exp 10/2023; 17220172, 17220251, Exp 12/2023.
- Risk classification
- Class III
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDASuccinylcholine Chloride Injection, USP, 200 mg/10 mL (20 mg/mL) syringe, packaged in 5 x 10 mL Pre-FilledJuly 27, 2022
- FDADifluprednate Ophthalmic Emulsion, 0.05%, 5ml bottles, Rx only, Mfd. by: Cipla Ltd., India At M/S IndocoJuly 27, 2022
- FDAAnticoagulant Sodium Citrate Solution, USP 4%, 200 mg/5 mL (40 mg/mL) syringe, packaged in 5 x 5 mL Pre-FilledJuly 27, 2022
- FDAAripiprazole Tablets, USP 20 mg, packaged in a) 1,000-count bottle (NDC 60505-2676-8, UPC 3 60505 26768 2), b)July 27, 2022
- FDA8.4% Sodium Bicarbonate Injection, USP, 4.2 g/50 mL (84 mg/mL) 1 mEq/mL syringe, packaged in 1 x 50 mLJuly 27, 2022
- FDAArtri Ajo King Reforzado con Ortiga y Omega 3 tablets, 500 mg, 100-count bottle, Hecho en Mexico por: PLANTASJuly 27, 2022
Questions about this recall
Was Aspirin and Extended-Release Dipyridamole Capsules, 25mg/200 mg, 60-count bottle, Rx Only, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, Product of India, NDC 68462-405-60. recalled?
Yes. FDA published recall D-1282-2022 on July 27, 2022. Reported hazard: Failed Tablet/Capsule Specification : Capsule breakage
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: ASPRIN AND EXTENDED-RELEASE DIPYRIDAMOLE. UPC: 0368462405604.